Welcome

The Vermont Center on Behavior and Health (VCBH), led by Director Stephen T. Higgins, PhD, is an interdisciplinary research center committed to investigating relationships between personal behavior patterns (i.e., lifestyle) and risk for chronic disease and premature death. Our work has historically focused on health disparities for the most vulnerable populations, particularly among the socioeconomically disadvantaged where these risk factors are overrepresented.

 

VCBH logo

Located in Burlington, VT at the University of Vermont, Larner College of Medicine, VCBH researchers have a specific focus on understanding mechanisms underpinning risk and developing effective interventions and policies to promote healthy behavior. A common thread across VCBH research projects is the application of knowledge from the disciplines of behavioral economics and behavioral pharmacology to increase understanding of vulnerability to unhealthy behavior and the use of incentives and other behavioral and pharmacological interventions to support healthy behavior change interventions and policies.

Stay Connected with VCBH

Join our mailing list to get the latest
on news and events.

Follow us on our social media channels

Twitter icon circle Facebook icon circle LinkedIn icon YouTube Icon

Upcoming VCBH Events

 

May Lecture Series: Michele Staton, PhD

Dr. Staton will be giving a remote presentation on the topic of the Kentucky Women’s Justice Community Opioid Innovation Network (JCOIN). Join us on Zoom!

Visit the Center on Rural Addiction

CORA_transparents

 


VCBH Career Opportunities

VCBH Center Administrator. Click here to apply.

Postdoctoral Research Fellowships. Click here for more information.

VCBH News

Incentives Could Enhance Adherence with COVID-19 Vaccination Schedule

January 11, 2021 by Nicole Twohig

While public health and infectious disease experts have discussed strategies to enhance adherence, including the potential use of financial incentives, an examination of the scientific evidence on incentivizing vaccine adherence has not been discussed. A new Commentary in Preventive Medicine by a team led by Stephen Higgins, Ph.D., director of the Vermont Center on Behavior and Health and professor of psychiatry at the University of Vermont’s Larner College of Medicine, addresses that gap.

As the United States struggles to control record-breaking increases in COVID-19 infections and hospitalizations, the roll-out of two approved vaccines offers tremendous hope for saving lives and curbing the pandemic. To achieve success, however, experts estimate that at least 70 to 90% of the population must be inoculated to achieve herd immunity, but how can we ensure folks will voluntarily receive a vaccine? 

Both vaccines require two injections. Pfizer-BioNTech’s second dose must be given 21 days after the first and Moderna’s second dose must be administered 28 days after the first. While public health and infectious disease experts have discussed strategies to enhance adherence, including the potential use of financial incentives, an examination of the scientific evidence on incentivizing vaccine adherence has not been discussed.

A new Commentary in Preventive Medicine  by a team led by Stephen Higgins, Ph.D., director of the Vermont Center on Behavior and Health (VCBH) and professor of psychiatry at the University of Vermont’s (UVM) Larner College of Medicine, addresses that gap. 

In their paper, Higgins and his VCBH research colleagues Elias Klemperer, Ph.D., and Sulamunn Coleman, Ph.D., describe results from several controlled trials that support the efficacy of incentivizing vaccine adherence. A strong example from their literature review focused on the impact of using incentive strategies to increase hepatitis B virus (HBV) vaccine adherence among injection drug users (IDUs). Individuals dependent on illicit drugs such as cocaine and heroin often face barriers ranging from co-occurring medical conditions to socioeconomic instability, which can make adhering to preventive medical regimens highly challenging. The HBV vaccine entails a three-dose regimen (typically at 0, 1, and 6 months) which has created adherence challenges among IDUs. 

Their systemic literature reviews found strong support for the use of incentives, including a 2019 meta-analysis of the literature showing that modest financial incentives resulted in a 7-fold increase in adherence compared to no incentives.

Higgins and his coauthors conclude “that financial incentives could be helpful in promoting the high levels of adherence to COVID-19 vaccines that experts project will be necessary for herd immunity.”

###

This letter received support in part from a Centers of Biomedical Research Excellence Award P20GM103644 from the National Institute of General Medical Sciences, and Institutional Training Grant Award T32DA07242 from the National Institute on Drug Abuse.